孟鲁司特钠对慢性阻塞性肺疾病急性加重期患者炎症因子、肺功能的影响  

Effect of montelukast sodium on inflammatory factors and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：汤晓凤[1] 刘旭春[1] TANG Xiao-feng;LIU Xu-chun(Department of Respiratory Medicine,Chizhou People s Hospital,Chizhou 247100,Anhui,China)

机构地区：[1]池州市人民医院呼吸内科,安徽池州247100

出　　处：《川北医学院学报》2019年第1期71-73,共3页Journal of North Sichuan Medical College

基　　金：安徽省池州市科技局科研项目(CZ-2011-13)

摘　　要：目的:探究孟鲁司特钠对慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者炎症因子、肺功能的影响。方法:按照不同的治疗方法,将70例AECOPD患者分为对照组和观察组,每组各35例。对照组给予抗感染、吸氧、化痰等常规治疗;观察组在常规治疗的基础上给予孟鲁司特钠,两组治疗时间均为2周。观察两组患者炎症因子、肺功能的变化,并评估治疗效果。结果:治疗后,两组患者炎症因子CRP、PCT检测水平明显下降,FEV1、FEV1/FVC、FEV1%Pred明显升高(P<0.05),且观察组的上述检测指标较对照组变化更为显著,差异有统计学意义(P<0.05);观察组的治疗总有效率(94.29%)高于对照组(77.14%),差异有统计学意义(P<0.05);两组均无明显异常不良反应。结论:AECOPD患者在常规对症治疗基础上给予孟鲁司特钠,可有效抑制炎症反应和改善肺功能,安全性较好,临床应用价值显著。Objective:To explore the effect of montelukast sodium on inflammatory factors and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:70 cases with AECOPD were divided into the control group and the observation group according to different treatment methods,and each group had 35 cases.The patients in the control group were given routine treatment,such as anti-infection,oxygen inhalation and phlegm resolving.The patients in the observation group were given routine treatment combined with montelukast sodium,the patients in the two groups were treated for 2 weeks.The changes of inflammatory factors and pulmonary function in the two groups were observed,and the therapeutic effect was evaluated.Results:After treatment,the levels of CRP,PCT in the two groups were significantly lower than those before treatment,and the levels of FEV1,FEV1/FVC and FEV1% Pred increased significantly(P<0.05).The above-mentioned indexes in the observation group changed more significantly than those in the control group,with statistical significance(P<0.05).The total effective rate in the observation group was 94.29%,which was higher than that(77.14%) in the control group,the difference was statistically significant(P<0.05).There was no obvious adverse reaction in the two groups.Conclusion:AECOPD patients treated with montelukast sodium on the basis of routine symptomatic treatment can effectively inhibit inflammatory reaction and improve lung function,with good safety and significant clinical application value.

关 键 词：慢性阻塞性肺疾病急性加重期 孟鲁司特钠 炎症因子 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]